GlaxoSmithKline-GSK has been marketing the unique preparation of Fluticasone Advair oral inhalation which has the combination of inhaled drugs which is used for treating asthma and chronic bronchitis. It is known that the airways – bronchioles through which the air is inhaled or exhaled to and from the lungs in asthma patients usually gets constricted due to the deposition of mucus, spasm of the muscles that surround such airways or inflammation of the lining of these airways. The constriction of the airways results in the symptoms of shortness of breath, wheezing, coughing and congestions.

When taken, Fluticasone – Advair the steroid which is used to prevent the discharge of substances in the body that may develop inflammation. Salmeterol – one of the components in Fluticasone – Advair is the bronchodilator which works by relaxing muscles in the airways for enabling improved breathing condition. Advair is generally used for averting asthma attacks but it does not treat the already begun asthma anyway. Advair is also used for treating the chronic obstructive pulmonary disease – COPD connected with the chronic bronchitis. Advair may also be used for the purposes other than those listed in the product medication guide as the doctor may desire.

The medications called bronchodilators widely used for treating asthma include those that open up the airways and diminish inflammation. The recommended doses for asthma in patients of 12 years and above age is 1 inhalation two times a day – morning and evening by maintaining the precise gap of about 12 hours. The lowest effective strength and the optimal dose recommended is 500mcg/50mcg two times a day for an average adult while for the children between age of 4 and 11 years are advised to take only one inhalation of 100mcg/50mcg twice every day.